Use of botulinum toxin type A in patients with erythematous-telangiectatic rosacea
https://doi.org/10.33667/2078-5631-2019-2-26(401)-100-104
Abstract
The article describes relevant data on the etiology of rosacea and the clinical forms of the disease. A pathogenetic substantiation of the feasibility of using botulinum toxin type A (BTA) with an erythematous-telangiectatic subtype of rosacea is given. A study was conducted involving 30 patients with ETR to treat the manifestations of this dermatosis using BTA injections in mesotechnics. As a result, we established a positive role for the use of BTA in ETP based on the use of a visual analogue scale (VAS), and also obtained data on the distribution of trigger factors and associated pathologies. We came to conclusions about the effectiveness of the botulinum toxin method for rosacea and the feasibility of further studies to optimize the dose and frequency of administration of type A botulinum toxin for a more pronounced and lasting result.
About the Author
O. A. Egorova
Yudino — Russian Scientific Centre for Medical Rehabilitation and Balneology
Russian Federation
Yudino, Moscow Region
Russian Federation
Yudino, Moscow Region
References
1. Chauhan N., Ellis D. A. Rosacea: pathophysiology and management principles // Facial Plast. Surg. Clin. North Am. 2013. Vol. 21. N 1. P. 127–136.
2. Steinhoff M., Schmelz M., Schauber J. Facial erythema of rosacea — aetiology, different pathophysiologies and Treatment Options. Acta Derm Venerеol 2015 Dec 30.
3. Wilkin J., Dahl M., Detmar M., Drake L., Feinstein A., Odom R. (2002) Standard classifi cation of rosacea: report of the National Rosacea Society Expert Committee on the classifi cation and staging of rosacea. J Am Acad Dermatol., 46 (4): 584–7.
4. Tan J, et al. Br J Dermatol 2013; 169 (3): 555–62.
5. Yuraitis M., Jacob C. I. Botulinum toxin for the treatment of facial flushing. Dermatol Surg 2004; 30 (1): 102–104.
6. Durham P. L., Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache 2004; 44: 35–42.
7. Bansal C., Omlin K. J., Hayes C. M., el al. Novel cutaneous uses for botulinum toxin type A. J Cosmet Dermatol 2006; 5: 268–272.
8. Мимов А. В. Комбинированное применение импульсного лазерного излучения и ультразвукового воздействия в лечении больных розацеа. Автореф. дис. на соискание ученой степени канд. мед. наук, 2013.
9. Yosipovitch G., Reis J., Tur E., et al. Sweat secretion, stratum corneum hydration, small nerve function and pruritus in patients with advanced chronic renal failure. Br J Dermatol 1995; 133: 561.
10. Izikson L, English JC, Zirwas MJ. The flushing patient: Differential diagnosis, workup, and treatment. J Am Acad Dermatol 2006; 55: 193–208.
11. Friedman BS, Germano P., Miletti J, Metcalfe DD. A clinicopathologic study of ten patients with recurrent unexplained flushing. J Allergy ClinImmunol 1994; 93: 53–60.
12. Eshghi G., Khezrian L., Alirezaei P. Botulinum Toxin A in Treatment of Facial Flushing. Acta Med Iran 2016 Jul; 54 (7): 454–7.
13. Круглова Л. С., Мурашкин Н. Н., Стенько А. Г., Агафонова Е. В. Рекомендации по применению ивермектина и бримонидина тартрата при различных подтипах розацеа. Москва, 2018.
14. Del Rosso J. Q., Gallo R. L., Tanghetti E. et al. An evaluation of potential correlation between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis 2013; 91 (suppl 3): 1–8.
15. Schwab V. D., Sulk M., Seeliger S. (2011) Neurovascular and Neuroimmune Aspects in the Pathophysiology of Rosacea. J Investig Dermatol Symp Proc., Vol. 15, No 1, pp. 53–62.
16. Scott J, Huskisson EC. Graphic representation of pain. Pain 1976; 2 (2): 175–184.
17. Потекаев Н. Н. Розацеа. М.-СПб: ЗАЩ «Издательство БИНОМ», «Невский диалект», 2000. 144 с.
18. Yuraitis M., Jacob C. I. Botulinum toxin for the treatment of facial flushing. Dermatol Surg 2004; 30 (1): 102–104.
19. Bharti J, Sonthalia S, Jakhar D. Mesotherapy with botulinum toxin for the treatment of refractory vascular and papulopustular rosacea. May 19, 2018.
20. Ferraro G, Altieri A, Grella E, D’Andrea F. Botulinum toxin: 28 patients affected by FREY’s syndrome treated with intradermal injections. Plastic and Reconstructive Surgery 2005; 115: 344–345.
Review
For citations:
Egorova O.A. Use of botulinum toxin type A in patients with erythematous-telangiectatic rosacea. Medical alphabet. 2019;2(26):100-104. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-26(401)-100-104
Views:
662
Email this article 